Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2022 | $18.00 | Buy | H.C. Wainwright |
| 7/5/2022 | $20.00 → $8.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/12/2021 | $21.00 → $22.00 | Outperform | SVB Leerink |
Combined Company to Trade on Nasdaq Under Ticker "TRML"Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris' stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris' common stock to the stockholders of Tourmaline Bio, Inc. ("Tourmaline") pursuant to the terms of the Agreement and Plan of Merger, dated as of June 22, 2023, pursuant to which a direct wholly owned subsidiary of Talaris will merge with a
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. ("Tourmaline") pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the sp
NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") announced today NYBCe's acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe's Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the bi
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
3 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
H.C. Wainwright initiated coverage of Talaris Therapeutics with a rating of Buy and set a new price target of $18.00
Morgan Stanley downgraded Talaris Therapeutics from Overweight to Equal-Weight and set a new price target of $8.00 from $20.00 previously
SVB Leerink reiterated coverage of Talaris Therapeutics with a rating of Outperform and set a new price target of $22.00 from $21.00 previously
Gainers Biocept, Inc. (NASDAQ:BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. Shift Technologies, Inc. (NASDAQ:SFT) shares rose 74.4% to $0.1878 in pre-market trading. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection. Connexa Sports Technologies Inc. (NASDAQ:CNXA) shares gained 45% to $2.45 in pre-market trading after gaining around 4% on Tuesday. RVL Pharmaceuticals plc (NASDAQ:RVLP) shares climbed 41.2% to $0.0720 in pre-market trading after falling 12% on Tuesday. RVL Pharmaceuticals said on Oct. 12,
8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)
424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)
Combined Company to Trade on Nasdaq Under Ticker "TRML"Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris' stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris' common stock to the stockholders of Tourmaline Bio, Inc. ("Tourmaline") pursuant to the terms of the Agreement and Plan of Merger, dated as of June 22, 2023, pursuant to which a direct wholly owned subsidiary of Talaris will merge with a
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. ("Tourmaline") pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the sp
NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") announced today NYBCe's acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe's Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the bi
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris's Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. "On behalf of the board, I would like to thank Scott for his unwavering commitment to patients and to Talaris over the past four and a half years," said Francois Nader, MD, Chairman of the Talaris Therapeutics Board of Directors. "I welcome M
All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection drugs Multiple oral and poster presentations at the American Transplant Congress (ATC) 2022 highlighted key research findings and long-term Phase 2 follow up Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company's Board of Directors. "Karen's long track record of developing and commercializing novel therapies and her wide-ranging industry experience make her a valuable addition to our Board of Directors," said Francois Nader, M.D., Chairman of the Board of Talaris. "I am pleased to welcome her to the team an